Clinical Trials Browser

Has results × Brain Neoplasms × pembrolizumab × Clear all

NCT02852655 2026-03-20

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Phase 1 Active not recruiting

60 enrolled 19 charts

Brain Neoplasms

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04479241 2025-06-05

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

Phase 2 Completed

25 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT02085070 2021-03-24

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Phase 2 Completed

65 enrolled 10 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma